Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Adachi, Yayoi ^a,b   Ishiguro, Junko ^a   Kotani, Haruru ^a   Hisada, Tomoka ^a   Ichikawa, Mari ^a   Gondo, Naomi ^a   Yoshimura, Akiyo ^a   Kondo, Naoto ^a   Hattori, Masaya ^a   Sawaki, Masataka ^a   Fujita, Takashi ^a   Kikumori, Toyone ^b   Yatabe, Yasushi ^a   Kodera, Yasuhiro ^b   Iwata, Hiroji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Invasive ductal carcinoma; Invasive lobular carcinoma; Luminal; Prognosis

Indexed keywords

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLASSIFICATION; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84961675210     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2275-4     Document Type: Article

References (19)

1. Rosen P. Rosen's breast pathology. 3rd ed. Philadelphia: Lippincott williams & wilkins; 2009.
2. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26(18):3006-14.
3. Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17(7):1862-69.
4. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat. 2012;133(2):713-23.
5. Lakhani S, Ellis I, Schnitt S, Tan P, van de Vijver M. WHO classification of tumours of the breast. 4th ed. Lyon: International agency for resurch on cancer; 2012.
6. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-81.
7. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
9. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-23.
10. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24(9):2206-23.
11. Biglia N, Maggiorotto F, Liberale V, Bounous VE, Sgro LG, Pecchio S, D'Alonzo M, Ponzone R. Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Eur J Surg Oncol. 2013;39(5):455-60.
12. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008;44(1):73-83.
13. Mersin H, Yildirim E, Gulben K, Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol. 2003;29(4):390-5.
14. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41-8.
15. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretiere JM, Bouita L, Cohen-Solal C, Cherel P, Rouesse J. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228-33.
16. DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M. Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors. Am J Surg Pathol. 1990;14(1):12-23.
17. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, Hurley J, Serreyn RF, Daems KK, Van Belle SJ. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29(4):361-7.
18. Engstrom MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. Histopathology. 2015;66(3):409-19.
19. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res. 2003;63(21):7167-75.